ICLR - ICON Public Limited Company

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
147.55
+2.46 (+1.70%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close145.09
Open144.89
Bid147.58 x 4000
Ask147.74 x 1200
Day's Range143.01 - 147.95
52 Week Range118.10 - 155.33
Volume130,938
Avg. Volume254,410
Market Cap7.964B
Beta (3Y Monthly)0.65
PE Ratio (TTM)24.19
EPS (TTM)6.10
Earnings DateJul 23, 2019 - Jul 29, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est156.54
Trade prices are not sourced from all markets
  • Teladoc (TDOC) Up 22% in a Year: Will the Rally Continue?
    Zacks14 hours ago

    Teladoc (TDOC) Up 22% in a Year: Will the Rally Continue?

    Teladoc's increasing visits and subscriptions are likely to aid revenue growth. This will further drive its share price.

  • Markit2 days ago

    See what the IHS Markit Score report has to say about ICON PLC.

    ICON PLC NASDAQ/NGS:ICLRView full report here! Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for ICLR with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ICLR. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $38 million over the last one-month into ETFs that hold ICLR are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Hedge Funds Have Never Been More Bullish On ICON Public Limited Company (ICLR)
    Insider Monkey7 days ago

    Hedge Funds Have Never Been More Bullish On ICON Public Limited Company (ICLR)

    Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge funds’ stock picking abilities to illustrate. The Standard and Poor’s 500 Index returned approximately 12.1% in 2019 (through May 30th). Conversely, hedge […]

  • ICON Public Limited Company (NASDAQ:ICLR): Financial Strength Analysis
    Simply Wall St.15 days ago

    ICON Public Limited Company (NASDAQ:ICLR): Financial Strength Analysis

    Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as ICON Public Limited...

  • LabCorp (LH) Closes Envigo Swap Deal, Expands in CRO Space
    Zacks15 days ago

    LabCorp (LH) Closes Envigo Swap Deal, Expands in CRO Space

    The conclusion of LabCorp's (LH) swap transaction will help enhance the company's Covance global nonclinical drug development capabilities with additional sites and resources.

  • Business Wire28 days ago

    ICON’s Acquisition of MeDiNova Research

    ICON plc, (ICLR) a global provider of drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device industries, today announced that it has acquired a majority shareholding in MeDiNova Research, a site network with research sites in key markets in Europe and Africa, and that it has the right to acquire the remaining shares in the company by Quarter 3 2020. The acquisition further enhances ICON’s patient recruitment capabilities in EMEA and complements ICON’s existing site network in the US, PMG Research.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of ICLR earnings conference call or presentation 2-May-19 2:00pm GMT

    Q1 2019 ICON PLC Earnings Call

  • Calculating The Fair Value Of ICON Public Limited Company (NASDAQ:ICLR)
    Simply Wall St.last month

    Calculating The Fair Value Of ICON Public Limited Company (NASDAQ:ICLR)

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...

  • Business Wirelast month

    ICON Awarded Clinical Research Team of the Year and Best in Health Economics and Outcomes Research

    ICON plc, (ICLR) a global provider of drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device industries, today announced that it has been awarded the Clinical Research Team of the Year (with Eli Lilly and Company), for the second consecutive year, and Best in Health Economics and Outcomes Research (with Bristol-Myers Squibb and LATITUDE, powered by AXON). The awards indicated are ICON’s third win for Clinical Research Team of the Year since the inaugural CARE Awards in 2016, and first win in the Best Health Economics and Outcomes Research category. ICON and Eli Lilly and Company won the award for the successful execution of a full-service Cardiovascular Outcomes Trial (CVOT), in which they were able to achieve exceptional patient retention despite early challenges.

  • ICON Launches New Patient Engagement Platform to Support Improved Patient Experience and Enrollment in Clinical Trials
    Business Wirelast month

    ICON Launches New Patient Engagement Platform to Support Improved Patient Experience and Enrollment in Clinical Trials

    ICON plc, (ICLR) a global provider of drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, today announced the release of its web based patient engagement platform, to provide patients with study specific information and connectivity with the nearest investigative site. The solution supplements patient recruitment outreach by sites and increases visibility of potential study participants for sponsors and sites. Patient recruitment specialists work with sponsors to develop outreach programs that incorporate the right mix of digital channels, traditional methods and patient advocacy partnerships to attract patients to a study branded website hosted on the platform.

  • ICON (ICLR) Q1 2019 Earnings Call Transcript
    Motley Fool2 months ago

    ICON (ICLR) Q1 2019 Earnings Call Transcript

    ICLR earnings call for the period ending March 31, 2019.

  • Icon PLC (ICLR) Beats Q1 Earnings and Revenue Estimates
    Zacks2 months ago

    Icon PLC (ICLR) Beats Q1 Earnings and Revenue Estimates

    Icon PLC (ICLR) delivered earnings and revenue surprises of 1.88% and 0.52%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Icon PLC: 1Q Earnings Snapshot

    The Dublin-based company said it had profit of $1.63 per share. The results topped Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for earnings ...

  • Business Wire2 months ago

    ICON Reports First Quarter 2019 Results

    Highlights

  • Icon PLC (ICLR) Reports Next Week: Wall Street Expects Earnings Growth
    Zacks2 months ago

    Icon PLC (ICLR) Reports Next Week: Wall Street Expects Earnings Growth

    Icon PLC (ICLR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • ICLR or HQY: Which Is the Better Value Stock Right Now?
    Zacks2 months ago

    ICLR or HQY: Which Is the Better Value Stock Right Now?

    ICLR vs. HQY: Which Stock Is the Better Value Option?

  • Do Hedge Funds Love ICON Public Limited Company (ICLR)?
    Insider Monkey2 months ago

    Do Hedge Funds Love ICON Public Limited Company (ICLR)?

    "Market conditions are changing. The continued rise in interest rates suggests we are in the early stages of a bond bear market, which could intensify as central banks withdraw liquidity. The receding tide of liquidity will start to reveal more rocks beyond what has been exposed in emerging markets so far, and the value of […]

  • Shareholders Are Thrilled That The ICON (NASDAQ:ICLR) Share Price Increased 213%
    Simply Wall St.2 months ago

    Shareholders Are Thrilled That The ICON (NASDAQ:ICLR) Share Price Increased 213%

    The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put in. But on a lighter note, a good company can see its share price rise well over 100%. For instance, t...

  • Business Wire4 months ago

    ICON Wins Multiple Categories in 2019 CRO Leadership Awards

    ICON plc, (ICLR) a global provider of drug development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, has won awards across several categories in the annual CRO Leadership Awards. ICON received 2019 CRO Leadership Awards in five categories, each further divided into three groups – Big Pharma, Small Pharma, and Overall.

  • GlobeNewswire4 months ago

    Report: Developing Opportunities within Amazon, Prospect Capital, Alliance Data, Duke Realty, Stellus Capital Investment, and ICON — Future Expectations, Projections Moving into 2019

    NEW YORK, Feb. 27, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.